What New Drugs Target Dopamine and Norepinephrine in ADHD?

PostedSeptember 30, 2025

UpdatedSeptember 30, 2025

ByMy Patient Advice

Author: Victoria Rowe, MSc | Reviewed by: Dr. Rebecca Fernandez, MBBS

Recent advancements in neuropharmacology have led to the development of novel medications targeting dopamine and norepinephrine systems for treating ADHD. These new drugs aim to address the underlying neurotransmitter imbalances associated with ADHD, offering alternative treatment options for individuals who may not respond to traditional therapies.

Novel Medications for Dopamine and Norepinephrine in ADHD

Novel medications for dopamine and norepinephrine in ADHD aim to fine-tune neurotransmitter balance with improved effectiveness and fewer side effects.

Viloxazine (Qelbree)

One of the newer non-stimulant medications approved for ADHD, Viloxazine, works by selectively targeting norepinephrine and serotonin reuptake. This medication is unique in its dual action, boosting norepinephrine levels while also influencing serotonin pathways, which can improve attention and impulse control. It has shown effectiveness in children and adolescents with ADHD, offering a viable option for those who cannot tolerate stimulant medications.

Dextroamphetamine-amphetamine extended-release (Adderall XR)

While not brand new, Adderall XR has undergone improvements to offer a more sustained release of dopamine and norepinephrine throughout the day, enhancing focus and reducing impulsivity. It provides longer-lasting symptom relief and is often used when traditional immediate-release formulations do not offer sufficient control over symptoms.

Dexmethylphenidate (Focalin XR)

This medication is a refined version of methylphenidate, a commonly used stimulant that targets dopamine and norepinephrine. Dexmethylphenidate is known to have fewer side effects and provides more consistent symptom relief for individuals with ADHD, making it a popular choice for those seeking better control over hyperactivity and inattention.

Conclusion

New dopamine and norepinephrine drugs for ADHD, like Viloxazine, Adderall XR, and Dexmethylphenidate, offer more precise and sustained relief for ADHD symptoms, expanding treatment options and providing better outcomes for many patients. These advances in neuropharmacology are enhancing ADHD management, especially for those who struggle with traditional medications.

Visit providers like ADHD Certify for personal consultations to learn more about the latest dopamine and norepinephrine treatments for ADHD.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Dopamine and norepinephrine systems.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.